{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:25:33Z","timestamp":1777321533019,"version":"3.51.4"},"reference-count":78,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Urothelial cancer accounts for approximately 3% of new cancer cases worldwide, with a high burden of disease in countries with medium and low human development indexes where its incidence and mortality are increasing. The purpose of this consensus is to develop statements on the evaluation and treatment of locally advanced and metastatic urothelial carcinoma that would further guide the clinical practice in Latin America. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> A systematic review of the literature was conducted by an independent team of methodologists. Then, a modified Delphi method was developed with clinical specialists from different Latin American countries. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Forty-two consensus statements, based on evidence, were developed to address the staging, the evaluation (suitability for chemotherapy, risk assessment, and biomarkers), and systemic treatment (first-line and subsequent therapies) of locally advanced or metastatic urothelial carcinoma. The statements made in this consensus are suggested practice recommendations in the Latin American context; however, the importance of a complete and individualized patient evaluation as a guide for therapeutic selection is highlighted. The availability and affordability of support tools for the evaluation of the disease, as well as specific therapies, may limit the application of the best practices suggested. <\/jats:p><\/jats:sec><jats:sec><jats:title>Recommendations<\/jats:title><jats:p> Therapeutic decisions need to be tailored to the context-specific clinical setting and availability of resources. Local research is promoted to improve outcomes for patients with this challenging cancer in Latin America. <\/jats:p><\/jats:sec>","DOI":"10.1200\/go.23.00244","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T20:59:23Z","timestamp":1706216363000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic\/Locally Advanced Urothelial Carcinoma"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":true,"given":"Ray","family":"Manneh Kopp","sequence":"first","affiliation":[{"name":"Sociedad de Oncolog\u00eda y Hematolog\u00eda del Cesar, Valledupar, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Galanternik","sequence":"additional","affiliation":[{"name":"Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas \u201cNorberto Quirno\u201d (CEMIC), Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio A.","family":"Schutz","sequence":"additional","affiliation":[{"name":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo, Sao Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Kater","sequence":"additional","affiliation":[{"name":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo, Sao Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6633-771X","authenticated-orcid":true,"given":"Allan","family":"Ramos-Esquivel","sequence":"additional","affiliation":[{"name":"Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San Jos\u00e9, Costa Rica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-9853","authenticated-orcid":true,"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[{"name":"Instituto Nacional del Enfermedades Neopl\u00e1sicas, Lima, Per\u00fa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-2854","authenticated-orcid":true,"given":"Nora","family":"Sobrevilla-Moreno","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerolog\u00eda, Cl\u00ednica de Tumores Genitourinarios, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2698","authenticated-orcid":true,"given":"Laura","family":"Bernal Vaca","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universitaria Colombia y Cl\u00ednica de Marly, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-7313","authenticated-orcid":true,"given":"Linda","family":"Ibat\u00e1-Bernal","sequence":"additional","affiliation":[{"name":"InValue Health Solutions, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-3408","authenticated-orcid":true,"given":"Susan","family":"Mart\u00ednez-Rojas","sequence":"additional","affiliation":[{"name":"InValue Health Solutions, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-912X","authenticated-orcid":true,"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"b2","unstructured":"International Agency for Research on Cancer, World Health Organization. Bladder Source: Globocan, The Global Cancer Observatory, 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30-Bladder-fact-sheet.pdf"},{"key":"b3","first-page":"15","volume":"8","author":"Saginala K","year":"2020","journal-title":"Med Sci"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211047352"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14872"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14281"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-02001-x"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011"},{"key":"b12","author":"Khauli R","journal-title":"JCO Glob Oncol"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-52"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7319"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3472"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1159\/000318985"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1002\/cmmi.116"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.180.4.1801045"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-015-0086-6"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-006-0361-8"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6722"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12608"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2017.1321579"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.07.018"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050700"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201193"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00404-6"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22031"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70275-8"},{"key":"b30","first-page":"855","volume":"3","author":"Hussain SA","year":"2012","journal-title":"Oncol Lett"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10762"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4599"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt015"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.07.111"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.11.010"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.042"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29826"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"b41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"b42","volume-title":"FDA Alerts Health Care Professionals and Oncology Clinical Investigators About an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (Pembrolizumab) or Tecentriq (Atezolizumab) as Monotherapy to Treat Urothelial Cancer With Low Expression of PD-L1","author":"U S Food and Drug Administration","year":"2018"},{"key":"b43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr156"},{"key":"b44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.052"},{"key":"b45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"b46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3394"},{"key":"b47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3018"},{"key":"b48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24313"},{"key":"b49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.089"},{"key":"b50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"b51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"b52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01213"},{"key":"b53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"b54","volume-title":"KEYNOTE-555 Supports 6-Week Pembrolizumab Dosing Schedule in Melanoma\u2014The ASCO Post","author":"Goodman A","year":"2020"},{"key":"b55","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170108"},{"key":"b56","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000099823.60465.e6"},{"key":"b57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"b58","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13925"},{"key":"b59","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz127"},{"key":"b60","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_323835"},{"key":"b61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"b63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6795"},{"key":"b64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"b65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"b66","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411"},{"key":"b67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00660-4"},{"key":"b68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2005.00663.x"},{"key":"b69","first-page":"47","volume":"25","author":"Albers P","year":"2002","journal-title":"Onkologie"},{"key":"b70","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i1.695"},{"key":"b71","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2"},{"key":"b72","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.06.115"},{"key":"b73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3147"},{"key":"b74","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13839"},{"key":"b75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000485"},{"key":"b76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2520"},{"key":"b77","doi-asserted-by":"publisher","DOI":"10.1159\/000526415"},{"key":"b78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2020.05.011"},{"key":"b79","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.06.007"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.23.00244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:57:03Z","timestamp":1709733423000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.23.00244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1200\/GO.23.00244"],"URL":"https:\/\/doi.org\/10.1200\/go.23.00244","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2300244"}}